PROJECT NAME


 Gemmus is a privately held biotechnology company focused on the development of innovative pharmaceutical products for the treatment of influenza and other viral infectious diseases. Using a novel, host-directed approach, we target the underlying cause of debilitating symptoms associated with influenza and ‘influenza-like-illness’ (ILI) by modulating the natural immune response to the disease. We are committed to developing “first-in-class, best-in-class” products that meet a major medical need.

Gemmus Pharma was founded in 2007 to commercialize in-licensed technology from a major pharmaceutical company. Gemmus’ lead candidate is a cardiovascular drug currently marketed in Asia that has been repurposed for use as a treatment for influenza. Gemmus has received support from the National Institute of Allergy and Infectious Disease (NIAID) and has completed a Series A round. The company has applied for and received an SBIR(NIH) and a QTDP competitive grant.  Gemmus plans to file an investigational new drug (IND) application with the FDA for treatment of influenza infections in 2014.